Telaprevir or simeprevir-based triple therapy for recurrent hepatitis C virus among living donor liver transplant recipients

Telaprevir or simeprevir-based triple therapy for recurrent hepatitis C virus among living donor liver transplant recipients - TVR or SMV-based triple therapy for recurrent HCV among LDLT recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013628

Enrollment

Registered

2014-04-04

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C after living donor liver transplantation

Interventions

Telaprevir or Simeprevir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Null responders during or after the preemptive treatment, fibrosing cholestatic hepatitis

Exclusion criteria

Exclusion criteria: other than the above

Design outcomes

Primary

Measure	Time frame
sustained virologic response rates	—

Countries

Japan

Contacts

Public ContactJunichi Kaneko

The University of Tokyo Hepato-Biliary-Pancreatic Surgery Division, and Artificial Organ and Transplantation Division

jkaneko-gi@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026